Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.310
-0.070 (-2.07%)
Nov 18, 2026, 10:50 AM EST - Market open
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year. That makes Aclaris Therapeutics the 33,207th largest employer in the world and 4,337th in the United States.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$87,685
Profits / Employee
-$1,090,877
Market Cap
525.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 73 | 9 | 14.06% | 69 | 4 |
| Dec 31, 2024 | 64 | -27 | -29.67% | 61 | 3 |
| Dec 31, 2023 | 91 | -14 | -13.33% | 86 | 5 |
| Dec 31, 2022 | 105 | 28 | 36.36% | 100 | 5 |
| Dec 31, 2021 | 77 | 17 | 28.33% | 72 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Ginkgo Bioworks Holdings | 485 |
| Wave Life Sciences | 317 |
| Sana Biotechnology | 142 |
| Helus Pharma | 100 |
| Orchestra BioMed Holdings | 86 |
| Crescent Biopharma | 80 |
| ArriVent BioPharma | 77 |
ACRS News
- 1 day ago - Aclaris Therapeutics price target lowered to $12 from $13 at Canaccord - TheFly
- 1 day ago - Aclaris shares drop 1.5% after Phase 2 trial fails to meet endpoints - TheFly
- 1 day ago - Aclaris Therapeutics downgraded to Neutral at Wedbush after AD trial miss - TheFly
- 1 day ago - Aclaris Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 2 days ago - Aclaris Therapeutics initiates ALPHA trial of modzatinib - TheFly
- 2 days ago - Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP) - GlobeNewsWire
- 2 days ago - Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - GlobeNewsWire